KR20120094472A - 신규한 복용 요법 및 치료 방법 - Google Patents

신규한 복용 요법 및 치료 방법 Download PDF

Info

Publication number
KR20120094472A
KR20120094472A KR1020127008847A KR20127008847A KR20120094472A KR 20120094472 A KR20120094472 A KR 20120094472A KR 1020127008847 A KR1020127008847 A KR 1020127008847A KR 20127008847 A KR20127008847 A KR 20127008847A KR 20120094472 A KR20120094472 A KR 20120094472A
Authority
KR
South Korea
Prior art keywords
days
weeks
administered
cancer
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020127008847A
Other languages
English (en)
Korean (ko)
Inventor
존 램버트
제임스 제이. 올리어리
죠앤 엘리자베스 사라 쉰들러
스티븐 웨이트먼
앨버트 친
Original Assignee
이뮤노젠 아이엔씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이뮤노젠 아이엔씨 filed Critical 이뮤노젠 아이엔씨
Publication of KR20120094472A publication Critical patent/KR20120094472A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020127008847A 2009-10-21 2010-10-21 신규한 복용 요법 및 치료 방법 Withdrawn KR20120094472A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25380409P 2009-10-21 2009-10-21
US61/253,804 2009-10-21

Publications (1)

Publication Number Publication Date
KR20120094472A true KR20120094472A (ko) 2012-08-24

Family

ID=43898626

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127008847A Withdrawn KR20120094472A (ko) 2009-10-21 2010-10-21 신규한 복용 요법 및 치료 방법

Country Status (13)

Country Link
US (1) US20110097345A1 (enExample)
EP (1) EP2490715A4 (enExample)
JP (1) JP2013508400A (enExample)
KR (1) KR20120094472A (enExample)
CN (1) CN102630165A (enExample)
AU (1) AU2010310577A1 (enExample)
BR (1) BR112012009250A2 (enExample)
CA (1) CA2775806A1 (enExample)
IL (1) IL219279A0 (enExample)
IN (1) IN2012DN02826A (enExample)
MX (1) MX2012004406A (enExample)
RU (1) RU2012120691A (enExample)
WO (1) WO2011050180A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
BR112012017642A2 (pt) * 2010-01-21 2016-04-12 Immunogen Inc composições e métodos para tratamento de câncer de ovário
EP2524929A1 (en) * 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
WO2014018563A2 (en) * 2012-07-23 2014-01-30 The Board Of Trustees Of The Leland Stanford Junior University Methods for the treatment of cancer
WO2014052876A1 (en) * 2012-09-28 2014-04-03 Immunogen Inc. Methods for increasing efficacy of cd56- based therapy
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
CN119185571A (zh) * 2013-05-14 2024-12-27 伊缪诺金公司 抗folr1免疫缀合物给药方案
NZ757964A (en) * 2013-10-08 2022-07-01 Immunogen Inc Anti-folr1 immunoconjugate dosing regimens
AU2015204766B2 (en) 2014-01-08 2020-08-13 The Board Of Trustees Of The Leland Stanford Junior University Targeted therapy for small cell lung cancer
EP3160513B1 (en) 2014-06-30 2020-02-12 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
CN109803660A (zh) * 2016-08-10 2019-05-24 细胞基因公司 复发性和/或难治性实体瘤和非霍奇金淋巴瘤的治疗
EP3541358A1 (en) 2016-11-21 2019-09-25 Eirion Therapeutics, Inc. Transdermal delivery of large agents
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
MX2020013466A (es) * 2018-06-26 2021-04-19 Immunogen Inc Inmunoconjugados dirigidos a adam9 y métodos para usarlos.
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
TW202210103A (zh) * 2020-06-04 2022-03-16 瑞典商生物創新國際有限公司 治療系統、方法及用途
US12030888B2 (en) 2021-02-24 2024-07-09 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
CN121152872A (zh) * 2023-05-10 2025-12-16 南京传奇生物科技有限公司 嵌合抗原受体及其使用方法
CN120053673B (zh) * 2025-02-11 2026-05-05 暨南大学 纳米前药及其制备方法和用途
CN120173115A (zh) * 2025-05-20 2025-06-20 苏州欣协生物科技有限公司 一种抗人cd56蛋白工程抗体及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US7303749B1 (en) * 1999-10-01 2007-12-04 Immunogen Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
CA2385528C (en) * 1999-10-01 2013-12-10 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
IL159422A0 (en) * 2001-09-20 2004-06-01 Cornell Res Foundation Inc Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate-specific membrane antigen
US20040126379A1 (en) * 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
US7374762B2 (en) * 2003-05-14 2008-05-20 Immunogen, Inc. Drug conjugate composition
WO2005000230A2 (en) * 2003-06-05 2005-01-06 Charles Achkar Methods of treating hyperproliferative cell disorders
US8101720B2 (en) * 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
CN101374545B (zh) * 2005-04-15 2012-03-28 免疫基因公司 消除肿瘤中的异质或混合细胞群体
AU2007302448C1 (en) * 2006-09-26 2019-02-14 Genmab A/S Combination treatment of CD38-expressing tumors
JP2011524421A (ja) * 2008-06-16 2011-09-01 イミュノジェン・インコーポレーテッド 新規の相乗効果
BR112012017642A2 (pt) * 2010-01-21 2016-04-12 Immunogen Inc composições e métodos para tratamento de câncer de ovário
US20120269827A1 (en) * 2011-04-01 2012-10-25 Immunogen, Inc. Compositions and Methods for Treatment of Ovarian, Peritoneal, and Fallopian Tube Cancer

Also Published As

Publication number Publication date
IL219279A0 (en) 2012-06-28
MX2012004406A (es) 2012-05-08
BR112012009250A2 (pt) 2017-06-20
EP2490715A1 (en) 2012-08-29
RU2012120691A (ru) 2013-11-27
US20110097345A1 (en) 2011-04-28
EP2490715A4 (en) 2013-06-26
CA2775806A1 (en) 2011-04-28
WO2011050180A1 (en) 2011-04-28
CN102630165A (zh) 2012-08-08
AU2010310577A1 (en) 2012-04-19
JP2013508400A (ja) 2013-03-07
IN2012DN02826A (enExample) 2015-07-24

Similar Documents

Publication Publication Date Title
US20110097345A1 (en) Novel dosing regimen and method of treatment
Trail et al. Antibody drug conjugates for treatment of breast cancer: novel targets and diverse approaches in ADC design
AU2016216585B2 (en) Drug conjugate composition
US20230110128A1 (en) Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor
JP2007500236A (ja) 組換え抗ｃｄ３０抗体とその使用
EP1531869A2 (en) Compositions and methods for treating cancer using maytansinoid cd44 antibody immunoconjugates and chemotherapeutic agents
CN116490213A (zh) 用于治疗癌症的人源化抗liv1抗体
CN101237881B (zh) 免疫偶联物剂型
Tumey Next generation payloads for ADCs
HK1174551A (en) Novel dosing regimen and method of treatment
AU2021349385A1 (en) Humanized anti-liv1 antibodies for the treatment of cancer
JP2026510595A (ja) サシツズマブ薬物複合体及びその調製
Shao et al. Research and development of highly potent antibody-based drug conjugates and fusion proteins for cancer therapy
HK40044344A (en) Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid
R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000